Peptides DB

Research-centric peptide and protocol reference hub

Muscle Building Peptide Stack: Evidence-Based Combinations

The defensible muscle-building peptide stacks — GH secretagogue stack (CJC + Ipa), GH-axis + healing, and IGF-1 augmentation — with what each adds and why training and protein remain the foundation.

By PeptidesDB EditorialPublished Jun 18, 20265 min read

The defensible muscle-building peptide stacks center on the GH secretagogue combination (CJC-1295 + Ipamorelin) with optional healing-peptide additions for training recovery. Realistic expectations: 1–4 kg of additional lean mass on top of training-driven baseline across 12–24 weeks at responsive doses. Training and protein remain the load-bearing factors; peptides are adjuvants. This article covers the major stack patterns, what each adds, and what doesn't belong in the stack.

For the per-class deep dive see peptides for muscle growth. For the within-GH-stack comparison see Ipamorelin vs CJC-1295.

Quick verdict table

Stack Cost / month Effect class Best for
CJC-1295 + Ipamorelin (base) $200–$400 GH-axis pulse amplification First-time muscle-building user
CJC-1295 + Ipamorelin + BPC-157 $300–$600 GH + healing for recovery Heavy training phase
CJC-1295 + Ipamorelin + Tesamorelin $400–$800 GH-axis stack (2 GHRH inputs) More advanced; visceral fat focus too
MK-677 standalone (oral) $100–$300 Sustained GH-axis activation Oral convenience; appetite useful for bulking
HGH ± Ipamorelin $500–$2000 Direct GH supply Documented deficiency, clinical supervision

The default stack: CJC-1295 + Ipamorelin

The most-cited muscle-building stack. Two complementary mechanisms — a GHRH analog and a GHRP — that activate different pituitary receptors simultaneously to produce a larger GH pulse than either alone.

Standard pattern:

  • CJC-1295 without DAC 100 mcg + Ipamorelin 200–300 mcg in a single SC injection.
  • 1–3× daily. Most-common: pre-bed (amplifies nocturnal GH pulse) and/or morning fasted.
  • 8–12 weeks on, 4 weeks off.

Expected effects across a 12-week cycle:

  • Sleep quality improvement — most consistent subjective effect.
  • Faster soreness clearance, more weekly training volume.
  • Modest lean-mass gain (1–3 kg) on top of training baseline.
  • Slight fat-mass reduction.
  • Skin and connective-tissue quality changes.

See Ipamorelin vs CJC-1295 for the within-stack mechanism details.

Add 1: BPC-157 for heavy training phases

When training volume or intensity is high enough to produce tendon irritation or chronic soreness, add BPC-157 as a recovery-support adjunct.

Pattern: BPC-157 250 mcg SC twice daily, daily, during the 4–6 week peak intensity block. Discontinue when the high-load block ends; restart if needed for the next block.

This is a supportive layer, not a muscle-growth driver. The case for it: the Wolverine Stack logic applied preventively. The case against: adds cost; adds injection burden; effect on training capacity is real but modest.

Add 2: Tesamorelin for advanced users

Tesamorelin (FDA-approved GHRH analog for HIV lipodystrophy) is sometimes added on top of CJC + Ipa for body-composition emphasis. The mechanism overlap with CJC means you're stacking two GHRH-type inputs — not as additive as the GHRH + GHRP combination, but useful for users specifically targeting visceral-fat reduction alongside muscle gain.

Pattern: Tesamorelin 1 mg SC at bedtime; CJC + Ipa morning fasted. 8–12 weeks.

Best for users who can afford the additional cost and want the visceral-fat-specific benefit. Not a first-stack choice.

Alternative: MK-677 standalone

For users who want oral dosing and continuous GH-axis support rather than discrete pulses, MK-677 (oral ghrelin-receptor agonist) is the standalone alternative.

Pattern: 12.5–25 mg orally once daily, 8–12 weeks on, 4 weeks off.

Expected effects:

  • Similar lean-mass and recovery effects to CJC + Ipa.
  • Pronounced appetite increase (useful for bulking; problematic for cutting).
  • Water retention (more than the injectable stack).
  • Possible fasting-glucose elevation long-term; monitor A1C.

MK-677 research profile.

Alternative: HGH ± Ipamorelin (clinical setting)

For users with documented adult GH deficiency under clinician care, FDA-approved HGH (Somatropin) is the standard treatment. Ipamorelin is sometimes added as a low-dose adjunct to preserve pulse rhythm during long-term HGH replacement.

Not relevant for the off-label "anti-aging GH" usage — that's not FDA-approved and is illegal to prescribe for that indication in the US.

What doesn't belong in the stack

  • A second GHRP (Hexarelin / GHRP-2 / GHRP-6) on top of Ipamorelin. Adds cortisol/prolactin spike risk; doesn't proportionally increase GH.
  • A second GHRH analog (Sermorelin) on top of CJC-1295. Same-receptor duplication; no additive benefit.
  • AOD-9604, HGH Fragment 176-191, MOTS-c "metabolic enhancers". No published evidence for additive muscle-mass effect.
  • High-dose IGF-1 LR3 without endocrinology supervision. Hypoglycemia risk; cancer-history concerns; receptor desensitization with chronic use.
  • CJC-1295 with DAC + Ipamorelin. The continuous CJC-with-DAC profile blunts the discrete-pulse benefit of co-administered Ipamorelin. Use CJC-without-DAC instead.

The base layer (more important than any peptide)

The peptides will not produce useful muscle gain without:

  • Progressive resistance training 3–5 days/week with sufficient volume and intensity in the relevant rep ranges (6–15 for hypertrophy).
  • Protein intake of 1.6–2.2 g/kg body weight daily.
  • Energy balance appropriate to the goal — slight surplus for muscle gain, slight deficit for body-composition cuts.
  • Sleep of 7–9 hours per night.

If any of these are missing, peptides won't substitute. If all are in place, peptides are real adjuvants.

A representative 16-week cycle

For a hypothetical intermediate lifter starting a muscle-building protocol:

  • Weeks -2 to 0 (preparation): Baseline labs (CMP, lipid, A1C, IGF-1, testosterone if relevant). DEXA scan if accessible. Establish training program + protein targets.
  • Weeks 1–12 (active cycle): CJC-1295 + Ipamorelin nightly. Optional BPC-157 added during peak-intensity training blocks. Training 3–5×/week. Protein 1.8 g/kg.
  • Week 6 check-in: Labs (IGF-1, fasting glucose). Adjust if needed.
  • Weeks 13–16 (washout): Stop peptides. Continue training and protein. Reassess composition. Decide on next cycle.

Expected outcome: 1–3 kg lean mass added beyond the training-alone baseline, with faster recovery and better sleep throughout.

Safety frame

GH-axis cycles require monitoring:

  • Baseline + 8-week + end-of-cycle: CMP, lipid panel, fasting glucose, HbA1c, IGF-1.
  • Watch for: fluid retention, joint discomfort, carpal-tunnel symptoms, glucose elevation.
  • Cancer-history exclusion for IGF-1-driving compounds (always).
  • See are peptides safe?, peptide side effects.

Where to go from here

This is informational, not medical advice.